Oncogenic KRAS: Signaling and Drug Resistance

RAS proteins play a role in many physiological signals transduction processes, including cell growth, division, and survival. The Ras protein has amino acids 188-189 and functions as GTPase. These proteins are switch molecules that cycle between inactive GDP-bound and active GTP-bound by guanine nuc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hyeon Jin Kim, Han Na Lee, Mi Suk Jeong, Se Bok Jang
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	KRAS GTPase signaling mutant inhibitor drug resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/08d2cd764940497dbfb63f5269529f3d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:08d2cd764940497dbfb63f5269529f3d
record_format	dspace
spelling	oai:doaj.org-article:08d2cd764940497dbfb63f5269529f3d2021-11-25T17:01:19ZOncogenic KRAS: Signaling and Drug Resistance10.3390/cancers132255992072-6694https://doaj.org/article/08d2cd764940497dbfb63f5269529f3d2021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5599https://doaj.org/toc/2072-6694RAS proteins play a role in many physiological signals transduction processes, including cell growth, division, and survival. The Ras protein has amino acids 188-189 and functions as GTPase. These proteins are switch molecules that cycle between inactive GDP-bound and active GTP-bound by guanine nucleotide exchange factors (GEFs). KRAS is one of the Ras superfamily isoforms (N-RAS, H-RAS, and K-RAS) that frequently mutate in cancer. The mutation of KRAS is essentially performing the transformation in humans. Since most RAS proteins belong to GTPase, mutated and GTP-bound active RAS is found in many cancers. Despite KRAS being an important molecule in mostly human cancer, including pancreatic and breast, numerous efforts in years past have persisted in cancer therapy targeting KRAS mutant. This review summarizes the biological characteristics of these proteins and the recent progress in the exploration of KRAS-targeted anticancer, leading to new insight.Hyeon Jin KimHan Na LeeMi Suk JeongSe Bok JangMDPI AGarticleKRASGTPasesignalingmutantinhibitordrug resistanceNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5599, p 5599 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	KRAS GTPase signaling mutant inhibitor drug resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	KRAS GTPase signaling mutant inhibitor drug resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Hyeon Jin Kim Han Na Lee Mi Suk Jeong Se Bok Jang Oncogenic KRAS: Signaling and Drug Resistance
description	RAS proteins play a role in many physiological signals transduction processes, including cell growth, division, and survival. The Ras protein has amino acids 188-189 and functions as GTPase. These proteins are switch molecules that cycle between inactive GDP-bound and active GTP-bound by guanine nucleotide exchange factors (GEFs). KRAS is one of the Ras superfamily isoforms (N-RAS, H-RAS, and K-RAS) that frequently mutate in cancer. The mutation of KRAS is essentially performing the transformation in humans. Since most RAS proteins belong to GTPase, mutated and GTP-bound active RAS is found in many cancers. Despite KRAS being an important molecule in mostly human cancer, including pancreatic and breast, numerous efforts in years past have persisted in cancer therapy targeting KRAS mutant. This review summarizes the biological characteristics of these proteins and the recent progress in the exploration of KRAS-targeted anticancer, leading to new insight.
format	article
author	Hyeon Jin Kim Han Na Lee Mi Suk Jeong Se Bok Jang
author_facet	Hyeon Jin Kim Han Na Lee Mi Suk Jeong Se Bok Jang
author_sort	Hyeon Jin Kim
title	Oncogenic KRAS: Signaling and Drug Resistance
title_short	Oncogenic KRAS: Signaling and Drug Resistance
title_full	Oncogenic KRAS: Signaling and Drug Resistance
title_fullStr	Oncogenic KRAS: Signaling and Drug Resistance
title_full_unstemmed	Oncogenic KRAS: Signaling and Drug Resistance
title_sort	oncogenic kras: signaling and drug resistance
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/08d2cd764940497dbfb63f5269529f3d
work_keys_str_mv	AT hyeonjinkim oncogenickrassignalinganddrugresistance AT hannalee oncogenickrassignalinganddrugresistance AT misukjeong oncogenickrassignalinganddrugresistance AT sebokjang oncogenickrassignalinganddrugresistance
_version_	1718412755907641344

Oncogenic KRAS: Signaling and Drug Resistance

Ejemplares similares